Alison Tree

About

Alison Tree is a leading clinical researcher in radiation oncology, with a primary focus on prostate cancer treatment and comparative effectiveness. Her key research areas include stereotactic body radiotherapy (SBRT) and the optimization of treatment pathways for localized prostate cancer (LPCa). Dr. Tree is best known for her central role in the PACE-A trial, an international phase 3 randomized controlled trial comparing SBRT to surgery for LPCa. This landmark study, published in 2023 and cited 31 times, directly addresses therapeutic equipoise by evaluating quality-of-life outcomes, providing critical evidence for shared decision-making. Her work has significantly advanced the contemporary management of prostate cancer, as reflected in her 2025 review (24 citations), which highlights the global burden of the disease and the need for effective, less invasive therapies. Dr. Tree also demonstrated early success in patient recruitment for randomized trials, as shown in her 2013 work on the PACE study (8 citations), underscoring her ability to conduct high-impact, practice-changing research. Her contributions are shaping the future of prostate cancer care, offering patients more personalized and evidence-based treatment options.

Research Focus

Key Achievements

Top Papers

1. 1
   PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.

   31 citations · 2023
2. 2
   The contemporary management of prostate cancer

   24 citations · 2025
3. 3
   Successful Patient Acceptance of Randomization Within the Pace Study (Prostate Advances in Comparative Evidence)

   8 citations · 2013

Key Collaborators

Contact & Links